Methotrexate in Crohn’s disease: a new face for an old drug?

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 10, 2016, Pages 1135-1144

  Cesarini, Monica ^a   Festa, Stefano ^b   Papi, Claudio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

anti TNF alfa agent; Crohn s disease; immunomodulator; Methotrexate; steroid free remission

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC PNEUMONITIS; ANOREXIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; LIVER TOXICITY; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOMA; MAINTENANCE DRUG DOSE; MULTICENTER STUDY (TOPIC); NAUSEA; OBSERVATIONAL STUDY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84988474791     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1080/17474124.2016.1185363     Document Type: Review

References (87)

1. B.N.Cronstein Molecular therapeutics:methotrexate and its mechanism of action. Arthritis Rheum. 1996;39:1951–1960.
2. M.E.Weinblatt, J.S.Coblyn, D.A.Fox, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818–822.
3. P.Cipriani, P.Ruscitti, F.Carubbi, et al. Methotrexate:an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014;10(11):1519–1530.
4. R.A.Kozarek, D.J.Patterson, M.D.Gelfand, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110(5):353–356.
5. B.G.Feagan, J.Rochon, R.N.Fedorak, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–297.•• Pivotal RCT demonstrating the efficacy of methotrexate monotherapy for inducing remission in steroid-dependent Crohn’s disease.
6. B.G.Feagan, R.N.Fedorak, E.J.Irvine, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342(22):1627–1632.•• Pivotal RCT demonstrating the efficacy of methotrexate monotherapy for maintaing remission in Crohn’s disease.
7. N.Chande, D.J.Tsoulis, J.K.MacDonald. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2013;4:CD000545.
8. E.Prefontaine, L.R.Sutherland, J.K.Macdonald, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;1:CD000067.
9. J.Maté-Jiménez, C.Hermida, J.Cantero-Perona, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227–1233.
10. S.Ardizzone, S.Bollani, G.Manzionna, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease:a randomised, investigator-blind study. Dig Liver Dis. 2003;35(9):619–627.
11. R.Oren, M.Moshkowitz, S.Odes, et al. Methotrexate in chronic active Crohn’s disease:a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997;92(12):2203–2209.
12. S.Arora, W.Katkov, J.Cooley, et al. Methotrexate in Crohn’s disease:results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46(27):1724–1729.
13. L.J.Egan, W.J.Sandborn, W.J.Tremaine, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 1999;13(12):1597–1604.
14. K.Visser, D.van der Heijde. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–1099.
15. D.Kurnik, R.Loebstein, E.Fishbein, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther. 2003;18(1):57–63.
16. J.W.McDonald, Y.Wang, D.J.Tsoulis, et al. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD003459.
17. V.Patel, Y.Wang, J.K.MacDonald, et al. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;8:CD006884.
18. A.Dignass, G.Van Assche, J.O.Lindsay, et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease:current management. J Crohns and Colitis. 2010;4(1):28–62.• A comprehensive review addressing the efficacy and safety of methotrexate in the treatment of inflammatory bowel disease.
19. D.R.Mack, R.Young, S.S.Kaufman, et al. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J Pediatr. 1998;132(5):830–835.
20. S.Uhlen, R.Belbouab, K.Narebski, et al. Efficacy of methotrexate in pediatric Crohn’s disease:a French multicenter study. Inflamm Bowel Dis. 2006;12(11):1053–1057.
21. D.Turner, A.B.Grossman, J.Rosh, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol. 2007;102(12):2804–2812.
22. M.Ravikumara, A.Hinsberger, C.H.Spray. Role of methotrexate in the management of Crohn’s disease. J Pediatr Gastroenterol Nutr. 2007;44(4):427–430.
23. B.Weiss, A.Lerner, R.Shapiro, et al. Methotrexate treatment in pediatric Crohn’s disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009;48(5):526–530.
24. B.Boyle, L.Mackner, C.Ross, et al. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr. 2010;51(6):714–717.
25. S.Willot, A.Noble, C.Deslandres. Methotrexate in the treatment of inflammatory bowel disease:an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis. 2011;17(12):2521–2526.
26. W.Sunseri, J.S.Hyams, T.Lerer, et al. Pediatric inflammatory bowel disease collaborative research group. Retrospective cohort study of methotrexate use in the treatment of pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(8):1341–1345.
27. D.Turner, E.Doveh, A.Cohen, et al. Efficacy of oral methotrexate in paediatric Crohn’s disease:a multicentre propensity score study. Gut. 2015;64(12):1898–1904.•• Retrospective cohort study with large sample size addressing the efficacy of methotrexate in children with Crohn’s disease.
28. S.M.Haisma, T.Lijftogt, A.Kindermann, et al. Methotrexate for maintaining remission in paediatric Crohn’s patients with prior failure or intolerance to thiopurines:a multicenter cohort study. J Crohns Colitis. 2015;9(4):305–311.
29. I.Hojsak, Z.Mišak, O.Jadrešin, et al. Methotrexate is an efficient therapeutic alternative in children with thiopurine-resistant Crohn’s disease. Scand J Gastroenterol. 2015;50(10):1208–1213.
30. T.H.Baron, C.D.Truss, C.O.Elson. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993;38(10):1851–1856.
31. M.Lémann, C.Chamiot-Prieur, B.Mesnard, et al. Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther. 1996;10(3):309–314.
32. L.Vandeputte, G.D’Haens, F.Baert, et al. Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis. 1999;5(1):11–15.
33. M.Lémann, T.Zenjari, Y.Bouhnik, et al. Methotrexate in Crohn’s disease:long-term efficacy and toxicity. Am J Gastroenterol. 2000;95(7):1730–1734.
34. R.Y.Chong, S.B.Hanauer, R.D.Cohen. Efficacy of parenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther. 2001;15(1):35–44.
35. S.Y.Soon, A.Ansari, M.Yaneza, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16(9):921–926.
36. B.H.Hayee, A.W.Harris. Methotrexate for Crohn’s disease:experience in a district general hospital. Eur J Gastroenterol Hepatol. 2005;17(9):893–898.
37. C.Charpignon, P.Beau. Methotrexate as single therapy in Crohn’s disease:is its long-term efficacy limited? Gastroenterol Clin Biol. 2008;32(2):153–157.
38. S.Din, A.Dahele, J.Fennel, et al. Use of methotrexate in refractory Crohn’s disease:the Edinburgh experience. Inflamm Bowel Dis. 2008;14(6):756–762.
39. E.Domènech, M.Mañosa, M.Navarro, et al. Long-term methotrexate for Crohn’s disease:safety and efficacy in clinical practice. J Clin Gastroenterol. 2008;42(4):395–399.
40. D.M.Nathan, J.H.Iser, P.R.J.Gibson. A single center experience of methotrexate in the treatment of Crohn’s disease and ulcerative colitis:a case for subcutaneous administration. Gastroenterol Hepatol. 2008;23(6):954–958.
41. M.Wahed, J.R.Louis-Auguste, L.M.Baxter, et al. Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine. Aliment Pharmacol Ther. 2009;30(6):614–620.
42. J.Hausmann, K.Zabel, E.Herrmann, et al. Methotrexate for maintenance of remission in chronic active Crohn’s disease:long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis. 2010;16(7):1195–1202.
43. R.Parker, A.Dixit, A.Fraser, et al. Clinical experience of methotrexate in Crohn’s disease:response, safety and monitoring of treatment. Postgrad Med J. 2010;86(1014):208–211.
44. N.Chande, I.Abdelgadir, J.Gregor. The safety and tolerability of methotrexate for treating patients with Crohn’s disease. J Clin Gastroenterol. 2011;45(7):599–601.
45. N.C.Suares, P.J.Hamlin, D.P.Greer, et al. Efficacy and tolerability of methotrexate therapy for refractory Crohn’s disease:a large single-centre experience. Aliment Pharmacol Ther. 2012;35(2):284–291.
46. Y.González-Lama, C.Taxonera, A.López-Sanromán, et al. Madrid Group for Study of Inflammatory Bowel Diseases (ENICMAD). Methotrexate in inflammatory bowel disease:a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol. 2012;24(9):1086–1091.
47. M.L.Seinen, C.Y.Ponsioen, N.K.de Boer, et al. Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11(6):667–672.•• Retrospective cohort study with large sample size addressing the efficacy and safety of methotrexate in adult Crohn’s disease patients.
48. S.Saibeni, S.Bollani, A.Losco, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44(2):123–127.
49. M.Camus, P.Seksik, A.Bourrier, et al. Long-term outcome of patients with crohn’s disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11(4):389–394.
50. A.G.Fraser, T.R.Orchard, D.P.Jewell. The efficacy of azathioprine for the treatment of inflammatory bowel disease:a 30 year review. Gut. 2002;50(4):485–489.
51. J.P.Gisbert, P.Nino, C.Cara, et al. Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis:prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther. 2008;28(2):228–238.
52. F.Magro, J.Santos-Antunes, F.Vilas-Boas, et al. Crohn’s disease outcome in patients under azathioprine:a tertiary referral center experience. J Crohns Colitis. 2014;8(7):617–625.
53. G.Costantino, F.Furfaro, A.Belvedere, et al. Thiopurine treatment in inflammatory bowel disease:response predictors, safety, and withdrawal in follow-up. J Crohns Colitis. 2012;6(5):588–596.
54. R.K.Weersma, F.T.Peters, L.E.Oostenbrug, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther. 2004;20(8):843–850.
55. D.J.de Jong, M.Goullet, T.H.Naber. Side effects of azathioprine in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2004;16(2):207–212.
56. R.B.Gearry, M.L.Barclay, M.J.Burt, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13(8):563–567.
57. L.Peyrin-Biroulet, P.Deltenre, N.de Suray, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease:meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
58. F.Baert, M.Noman, S.Vermeire, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608.
59. J.F.Colombel, W.J.Sandborn, W.Reinisch, et al. SONIC study group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.
60. Y.P.Goekoop-Ruiterman, J.K.de Vries-Bouwstra, C.F.Allaart, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study):a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–3390.
61. F.C.Breedveld, M.H.Weisman, A.F.Kavanaugh, et al. The PREMIER study:a multicenter, randomized, double-blind clinical trial of combination therapy withadalimumab plus methotrexate versus methotrexatealone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
62. J.S.Smolen, D.M.Van DerHeijde, E.W.St Clair, et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab:results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702–710.
63. B.G.Feagan, J.W.McDonald, R.Panaccione, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–688.•• Randomised controlled trial comparing combination therapy methotrexate and infliximab vs infliximab monotherapy in patients with Crohn’s disease.
64. S.Vermeire, M.Noman, G.Van Assche, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231.• This study suggests that methotrexate is as effective as thiopurines in reducing the immunogenicity of infliximab in Crohn’s disease.
65. S.Ben–Horin, M.Waterman, U.Kopylov, et al. Antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(4):444–447.
66. A.Kandiel, A.G.Fraser, B.I.Korelitz, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54(8):1121–1125.
67. L.Beaugerie, N.Brousse, A.M.Bouvier, et al. CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease:a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625.
68. D.S.Kotlyar, M.T.Osterman, R.H.Diamond, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.
69. L.Beaugerie. Lymphoma:the bête noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology. 2013;145(5):927–930.
70. V.Annese, L.Beaugerie, L.Egan, et al. European evidence-based consensus:inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9(11):945–965.
71. H.H.Herfarth, M.D.Long, K.L.Isaacs. Methotrexate:underused and ignored? Dig Dis. 2012;30(Suppl 3):112–118.
72. R.B.Stein, S.B.Hanauer. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23(5):429–448.
73. No authors listed. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid arthritis clinical trial archive group. J Rheumatol. 1995;22(2):218–223.
74. J.A.Thomas, G.P.Aithal. Monitoring liver function during methotrexate therapy for psoriasis:are routine biopsies really necessary? Am J Clin Dermatol. 2005;6(6):357–363.
75. H.S.Te, T.D.Schiano, S.F.Kuan, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95(11):3150–3156.
76. D.Laharie, J.Seneschal, T.Schaeverbeke, et al. Assessment of liver fibrosis with transient elastography and fibrotest in patients treated with methotrexate for chronic inflammatory diseases:a case-control study. J Hepatol. 2010;53(6):1035–1040.
77. M.R.Fournier, J.Klein, G.Y.Minuk, et al. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol. 2010;105(7):1620–1626.
78. J.A.CooperJr, D.A.White, R.A.Matthay. Drug-induced pulmonary disease:cytotoxic drugs. Part 1. Am Rev Respir Dis. 1986;133(2):321–340.
79. G.S.Alarcón, J.M.Kremer, M.Macaluso, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356–364.
80. G.Margagnoni, V.Papi, A.Aratari, et al. Methotrexate-induced pneumonitis in a patient with Crohn’s disease. J Crohns Colitis. 2010;4(2):211–214.
81. C.Salliot, D.van der Heijde. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis:a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–1104.
82. F.Wolfe, K.Michaud. Lymphoma in rheumatoid arthritis:the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740– 1751.•• A large prospective study in patients enrolled in the National Data Bank for Rheumatic Diseases addressing the risk of lymphoma in patients with rheumatoid arthritis.
83. M.Del Campo, K.Kosaki, F.C.Bennett, et al. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology. 1999;60(1):10–12.
84. Administration FDA. Regulations. 1980;44:37434–37467.
85. C.J.van der Woude, S.Ardizzone, M.B.Bengtson, et al. European Crohn’s and colitis organization. The second European evidence-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107–124.
86. U.Mahadevan, S.Kane. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131(1):283–311.
87. J.A.Martínez Lopez, E.Loza, L.Carmona. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol. 2009;27(4):678–684.